The European Perspective
First Gene Therapy Trial to Reverse Cellular Aging
The first human patient has received gene therapy to reverse retinal cell aging, making them behave identically to young cells (The Guardian). This epigenetic reprogramming tests Europe’s regulatory frameworks, which prioritize symptom management over root-cause age reversal. Regulators treat aging as a natural process, not a disease, creating legal barriers for therapies unless they target specific physical ailments. While systemic human age reversal carries massive, unknown cancer risks that fundamentally justify strict regulatory caution, the current therapy is limited to highly specific retinal cells.
Collapse of European Bank Bail-In Credibility
Following the March 2023 Credit Suisse failure, where Swiss authorities bypassed resolution plans to guarantee a UBS takeover, spreads on European bank debt permanently narrowed. Markets discount the likelihood of a bail-in, a framework forcing bondholder losses before taxpayer money is used. Analysis by the Centre for Economic Policy Research (CEPR), a network of European economists, confirms investors price in lower bail-in probabilities, signaling a structural credibility decline in the post-2008 resolution framework.
EU Parliament Midterm Reshuffle
The European Parliament’s 719 lawmakers begin a six-week recess, returning August 31 to negotiate the institution’s midterm reshuffle (Politico). This restructuring determines committee leadership, directly allocating legislative control over the bloc’s industrial resources.
Catch the next Gist for further structural updates.
|
Leave a Reply